Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate virtually at the following upcoming investor conferences:

• The H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, on-demand beginning at 7:00 a.m. ET; and
• The Cantor Virtual Global Healthcare Conference on September 30, 2021 at 3:20 p.m. ET.

Webcasts of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the conference webcasts will be available on Concert’s website for two weeks following the presentations.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005021/en/

Justine Koenigsberg
(781) 674-5284
[email protected]

Source: Concert Pharmaceuticals, Inc.

You May Also Be Interested In

• ESS to Present at Sidoti Micro-Cap Virtual Conference
• In HelloNation, Chiropractic Care Expert Andrew Yakubik, D.C., Explains Sciatic Nerve Compression and Lower Back Pain Treatment
• John Kim Turns $0.80 Ticket Into $42,700 Mini Phil's Thrill Win at Americas Cardroom